icone plus
Contact
Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité DUPIXENT (dupilumab).
See also
Décision d'accès précoce
14/11/2024
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
4d3VeFP9RW6Kwz6Q